There's never a shortage of losers in the stock market. Let's take a closer look at five of this past week's biggest sinkers.


April 11

Weekly Loss

voxeljet AG (NYSE:VJET)



World Wrestling Entertainment (NYSE:WWE)



NQ Mobile (NYSE:NQ)



Kandi Technologies (NASDAQ:KNDI)



Halo Therapeutics (NASDAQ:HALO)



Source: Barron's.

Let's start with voxeljet. It was a brutal week for 3-D printing stocks, but Germany's voxeljet made things worse by going through with a secondary stock offering. It had to price the 3 million shares at $15, and that's harsh when one considers that the stock was trading as high as $70 late last year. 

Wrestling fans were stunned last weekend when Undertaker lost his bout in World Wrestling Entertainment's WrestleMania 30. He had won 21 consecutive fights before, and his scripted defeat came at the hands of an unlikely challenger. However, it was shareholders who were stunned on Monday, when a negative Barron's article and uninspiring video subscription data sent the shares lower. The league of grapplers announced that 667,287 subscribers have signed up to its online network since its February launch. Folks are paying $10 a month for online access that includes the pay-per-view events. It's an encouraging number on the surface, but growing that figure from here will be difficult as most diehard wrestling fans signed up ahead of WrestleMania 30. 

NQ Mobile slumped after falling short on the bottom line in its latest quarter. The Chinese provider of mobile Internet services had no problem topping Wall Street's revenue forecast, but it posted just $0.22 a share in adjusted earnings. Analysts were targeting $0.32 a share for the period. 

Kandi has been shifting into reverse and flooring it for the past three weeks with declines of 15%, 13%, and another 13% this past week. The Chinese maker of electric vehicles has come up twice in that span on CNBC's Mad Money's, with host Jim Cramer suggesting that investors "sell, sell, sell" the stock.

Halozyme Therapeutics surrendered nearly a third of its value a week earlier after after suspending a clinical trial for a pancreatic cancer treatment. Too many patients on the drug during the trial were experiencing blocked blood vessels, and Halozyme was hoping that the suspension would be temporary. The prior week's 30% spill carried over into a 12% drop this time around. The rotation out of biotechs didn't help Halozyme's chances of bouncing back.

Ready for a bounce
If you owned some of these losers, how about following the smart money into winners? Consider that David Gardner has proved the critics wrong time, and time, and time again with stock returns like 926%, 2,239%, and 4,371%. In fact, just recently one of his favorite stocks became a 100-bagger. And he's ready to do it again. You can uncover his scientific approach to crushing the market and his carefully chosen six picks for ultimate growth instantly, because he's making this premium report free for you today. Click here now for access.

Rick Munarriz and The Motley Fool have no position in any stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.